Parving HH - Search Results

1

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Among authors: parving hh. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.

2

Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy.

Sørensen VB, Rossing P, Tarnow L, Parving H, Nørgaard T, Kastrup J. Sørensen VB, et al. Clin Sci (Lond). 1998 Dec;95(6):709-17. doi: 10.1042/cs0950709. Clin Sci (Lond). 1998. PMID: 9831696 Clinical Trial.

3

Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study.

Rossing P, Hougaard P, Parving HH. Rossing P, et al. Among authors: parving hh. Diabetes Care. 2002 May;25(5):859-64. doi: 10.2337/diacare.25.5.859. Diabetes Care. 2002. PMID: 11978681

4

Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH. Andersen S, et al. Among authors: parving hh. Kidney Int. 2002 Jul;62(1):192-8. doi: 10.1046/j.1523-1755.2002.00410.x. Kidney Int. 2002. PMID: 12081578 Free article. Clinical Trial.

5

Optimal dose of losartan for renoprotection in diabetic nephropathy.

Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Andersen S, et al. Among authors: parving hh. Nephrol Dial Transplant. 2002 Aug;17(8):1413-8. doi: 10.1093/ndt/17.8.1413. Nephrol Dial Transplant. 2002. PMID: 12147788

6

Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.

Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH. Rossing K, et al. Among authors: parving hh. Diabetes Care. 2003 Jan;26(1):150-5. doi: 10.2337/diacare.26.1.150. Diabetes Care. 2003. PMID: 12502672 Clinical Trial.

7

Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.

Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving HH. Andersen S, et al. Among authors: parving hh. Nephrol Dial Transplant. 2003 Feb;18(2):293-7. doi: 10.1093/ndt/18.2.293. Nephrol Dial Transplant. 2003. PMID: 12543883

8

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Gaede P, et al. Among authors: parving hh. N Engl J Med. 2003 Jan 30;348(5):383-93. doi: 10.1056/NEJMoa021778. N Engl J Med. 2003. PMID: 12556541 Free article. Clinical Trial.

9

Smoking and progression of diabetic nephropathy in type 1 diabetes.

Hovind P, Rossing P, Tarnow L, Parving HH. Hovind P, et al. Among authors: parving hh. Diabetes Care. 2003 Mar;26(3):911-6. doi: 10.2337/diacare.26.3.911. Diabetes Care. 2003. PMID: 12610058

10

Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.

Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH. Hovind P, et al. Among authors: parving hh. Diabetes Care. 2003 Apr;26(4):1258-64. doi: 10.2337/diacare.26.4.1258. Diabetes Care. 2003. PMID: 12663607

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

670 results

Search Page

Filters